RE:RE:RE:New Cannabis Ventures I posted the below information sometime ago but it demonstrates Supreme is not valuated as its peers, and will be surpassing some while closing the gap on others.. I believe the majority believe Beena only acts when she can deliver in an ethical manner. Since Q2 release the reviews are great, Beena is slowly becoming more visible and every move she makes in my opinion is adding value to shareholders.
Looking at the below information, its only a matter of time for investors to realize Supreme business plan and fundamentals are superior to most in the industry. For the present state of the industry Supreme's template is the envy of most.
Somehow investors get drawn to the shiny objects ie: Canopy, Aurora etc. Due diligence at the moment is showing me Supreme is on a solid foundation moving forward, while many are struggling to justify their current MC and SP.
SP of $41.72,Canopy net revenue 153 million, net loss 829 million, adjusted ebitda loss 68 million for 3rd quarter 2021, and I could go on and on with other companies.
Organigram: SP $3.94
Q1 2021 net revenue of $19.3 million
Q1 2021 negative adjusted EBITDA of $6.4 million
Net loss:Q1 2021 net loss of $34.3 million
Cronos: SP $12.61
Third Quarter 2020
Net revenue of $11.4 million in Q3 2020
Reported operating loss of $41.2 million
Cronos Group (NASDAQ: CRON) has been one of the safer pot stocks to invest in, if for no other reason than it is backed by tobacco giant Altria, which owns a 45% stake in the business. But beyond that, Cronos hasn't given investors much reason to buy in. With relatively low sales numbers and operating losses in each of the past four quarters, its financials aren't all that impressive.
Sundial Growers: SP $1.30 Outstanding shares 1.56 billion
Net loss was $71.4 million in the third quarter; adjusted EBITDA loss increased by 13% over the previous quarter to $4.4 million
Net cannabis revenue for the third quarter of 2020 was $12.9 million
SUPREME SP $.29 with premium product at scale and with outstanding Q2, IMHO